10X Infringes Bio-Rad Patents, Federal Circuit Affirms
Law360 (May 28, 2021, 9:18 PM EDT) -- The Federal Circuit on Friday upheld the U.S. International Trade Commission's finding that 10X Genomics infringed Bio-Rad Laboratories' patents on microfluidic chips used for genetic sequencing, rejecting 10X's argument that the ITC used an incorrect claim construction.
The two companies are embroiled in multiple patent suits, and in April, the appeals court affirmed a separate ITC ruling that Bio-Rad infringed 10X's patents on similar technology. 10X was started by some of the founders of a company called QuantaLife, which was acquired by Bio-Rad in 2011, leading them to depart and form 10X.
In Friday's decision, the Federal Circuit found that the...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!